^
Phase 1
Boehringer Ingelheim
Active, not recruiting
Last update posted :
06/11/2024
Initiation :
06/11/2019
Primary completion :
09/03/2024
Completion :
05/30/2026
TP53 • MDM2
|
TP53 mutation • TP53 wild-type • TP53 amplification
|
brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Phase 1
Boehringer Ingelheim
Completed
Last update posted :
07/28/2023
Initiation :
02/23/2018
Primary completion :
07/20/2023
Completion :
07/20/2023
EGFR • ALK
|
PD-L1 expression • ALK rearrangement
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)
Phase 1
Boehringer Ingelheim
Completed
Last update posted :
06/29/2023
Initiation :
06/13/2017
Primary completion :
03/09/2023
Completion :
06/06/2023
EGFR • ALK • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type
|
ezabenlimab (BI 754091) • miptenalimab (BI 754111)